Showing results (481-490 of 585) with videos related to
Sort By:
Pageof 59
European Journal of Gastroenterology & Hepatology|April 14, 2020
Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Oncology|April 27, 2021
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting AnalysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|November 30, 2021
Active and passive smoking and risk of ulcerative colitis: A case-control study in JapanAtsushi Nishikawa, Keiko Tanaka, Yoshihiro Miyake, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 18, 2025
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus EliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.Journal of Gastroenterology|October 1, 2020
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter studyYuki Tahata, Hayato Hikita, Satoshi Mochida, et al.Cytokine|May 14, 2022
IL12B rs6887695 polymorphism and interaction with alcohol intake in the risk of ulcerative colitis in JapanYoshihiro Miyake, Keiko Tanaka, Chisato Nagata, et al.European Journal of Gastroenterology & Hepatology|June 22, 2026
Dietary B vitamin intake and risk of ulcerative colitis: a case-control studyYoshihiro Miyake, Keiko Tanaka, Chisato Nagata, et al.Journal of Gastroenterology|June 20, 2025
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosisNaoki Kawagishi, Goki Suda, Yuki Tahata, et al.Gastroenterology Report|May 24, 2021
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Liver Cancer|May 12, 2021
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Pageof 59